August 17, 2026
Ikarovec CEO Tom Ciulla discusses their novel dual-function gene therapy targeting geographic atrophy by combining neuroprotection with complement modulation.
August 13, 2026
Nykode's CEO & CSO on building a global biotech from Norway, the cancer vaccine resurgence, navigating rapid growth, and fostering a winning culture.
August 10, 2026
MediciNova's CBO discusses their lean model, late-stage ALS asset MN-166, and the pivotal trial data expected to be a transformational catalyst.
August 7, 2026
Artiva CEO Fred Aslan on his VC-to-operator journey, the strategic pivot to autoimmune, and building the future of off-the-shelf NK cell therapy.
August 6, 2026
Evommune CEO Luis Pena on the startup mindset: courage, portfolio discipline, and a resilient culture are key to navigating biotech's challenges.
August 4, 2026
Corsera Health CFO Meredith Kaya on preventing cardiovascular disease with AI-powered lifetime risk prediction and proactive RNAi therapeutics.
VC Dana Watt on biotech's new playbook: Platform-first models, capital efficiency, and strategic outsourcing are key to building fundable companies.
August 3, 2026
Lyora Therapeutics CEO Pam Stetkiewicz on launching an asset-driven biotech to develop "one and done" AAV gene therapies for retinal diseases.
July 30, 2026
Constructive Bio CEO Ola Wlodek on rewriting the genetic code to create novel therapeutics beyond nature's limits and building a generational company.
July 23, 2026
Ona Therapeutics CEO Valerie Vanhooren on building a biotech, fundraising an $86M Series B, and developing novel ADCs for advanced cancers.
July 22, 2026
Ray Therapeutics' CEO Paul Bresge on his patient-centric mission to develop novel optogenetics gene therapies for late-stage blindness.
July 20, 2026
Haya Therapeutics CEO Samir Ounzain discusses leveraging AI to unlock the genome's 'dark matter' for chronic diseases and his journey to CEO.
July 16, 2026
Skeletalis CEO Ben Swanson discusses pioneering precision medicine for osteoporosis with the Oasis platform, a targeted therapy for bone diseases.
July 14, 2026
Beren Therapeutics' SVP Commercial, Bennett Smith, discusses why early commercial strategy is vital for biotech success, even when in stealth mode.
July 13, 2026
Miles Gerson of SV Health Investors discusses the rising momentum in neurodegeneration, tackling biomarkers, the blood-brain barrier, and new capital.
July 10, 2026
Inventiva CEO Andrew Obenshain on leading French biotechs, the lessons from Bluebird's cash struggles, and advancing a Phase 3 MASH therapy.
July 6, 2026
Foresite Capital's Michael Rome on biotech investing, navigating market cycles, and identifying differentiated biology in a tough environment.
June 19, 2026
Zura Bio CEO Sandeep Kulkarni on his journey from investor to founder, biotech strategy, disciplined capital allocation, and building for an exit.
June 17, 2026
Kainova Therapeutics CEO Sean MacDonald discusses the company's strategic rebrand, unlocking GPCR potential, and building a resilient global team.
June 11, 2026
CEL-SCI CEO Geert Kersten discusses a non-toxic immunotherapy for head & neck cancer, navigating FDA hurdles & pioneering market entry in Saudi Arabia.
June 10, 2026
Citius Pharma CEO Leonard Mazur on building companies from scratch, the power of a great team, strategic niche focus, and a resilient mindset.
June 6, 2026
Luson Bioventures' Derek Small on his operator-led approach to venture creation, a deep focus on neuroscience, and building biotech in tough cycles.
June 2, 2026
Biocon Biologics' CCO Matt Erick on leveraging vertical integration and scale to lead the upcoming $175B wave of biosimilar opportunities.
June 1, 2026
Thalia Therapeutics CEO David Solomon discusses the company's pivot to dual-acting RNA therapies, targeting complex cardiovascular disease and beyond.
May 26, 2026
Priovant CEO Ben Zimmer discusses building a company focused on rare autoimmune diseases, leading by example, and their path to a potential FDA approval.
Navigator Medicines CEO Tosh Butt on challenging Big Pharma, innovating in Hidradenitis Suppurativa, and using agile biotech strategies.
May 22, 2026
Autobahn Therapeutics' CEO Kevin Finney on de-risking CNS drug development by pairing validated biology with a proprietary prodrug platform.
May 21, 2026
Axonis Therapeutics' Shane Hegarty on pioneering a first-in-class KCC2 drug to restore inhibitory balance in CNS disorders like epilepsy & pain.
May 20, 2026
Leal Therapeutics CEO Asa Abeliovich on leveraging human genetics and neurometabolism to create novel therapies for CNS disorders like schizophrenia & ALS.
May 18, 2026
Neurvati CEO Bruce Leuchter on their Blackstone-backed model, capitalizing on the neuroscience resurgence with a data-driven, people-first approach.
May 12, 2026
Bausch Health R&D Head Jonathan Sadeh on his Big Pharma journey, navigating large orgs, adapting to R&D evolution, and driving agile innovation.
May 11, 2026
Resvita Bio's CEO & CTO discuss their platform using engineered bacteria for continuous protein therapy to treat rare skin diseases.
May 7, 2026
nChroma Bio's CSO & CDO discuss their epigenetic editing platform, its lead Hepatitis B program, and building an innovative biotech culture.
May 6, 2026
Jade Biosciences CEO Tom Frohlich on building a leading autoimmune company with a multi-asset pipeline, strong culture, and a transformational year ahead.
April 30, 2026
Cardurion CPO Karen Lewis on career pivots, navigating big pharma vs. biotech, and preserving culture through growth and change.
April 29, 2026
AAVantgarde's CEO discusses a novel dual AAV platform for delivering oversized genes to treat inherited retinal diseases like Stargardt and Usher.
April 27, 2026
Coya Therapeutics CEO Arun Swaminathan discusses leveraging Nobel Prize-winning T-reg science to tackle ALS and his strategy for biotech success.
April 23, 2026
Iolyx Therapeutics CEO Elizabeth Jeffords on applying oncology lessons to immuno-ophthalmology and pioneering targeted therapies for eye disease.
April 22, 2026
Stellular Bio CEO Derek Adams on advancing PRB therapies for severe dry eye, navigating tough capital markets, and the transition to CEO.
April 21, 2026
Complement Therapeutics CEO Rafiq Hasan discusses dosing the first patient in a gene therapy trial for eye disease using an innovative design.
April 20, 2026
Enviva Biotech CEO Lu Han on building a global CAR-T company by merging China's discovery speed with US/EU clinical and regulatory expertise.
April 16, 2026
Therna Bio's CEO Nazli Azimi on using proprietary biological data to fuel AI platforms that design programmable RNA medicines for rare diseases.
MRM Health CEO Sam Possemiers on their CORAL platform, advancing microbial therapies for IBD, and raising a €55M Series B in a tough market.
April 15, 2026
Atai Beckley CEO Srinivas Rao discusses the company's evolution, the psychedelic hype cycle, and its pipeline of rapid mental health therapies.
OMX Ventures' Dan Fero on investing at the intersection of biology, data, and AI, sharing insights on raising a fund and biotech market trends.
April 14, 2026
Poolbeg Pharma CEO Jeremy Skillington on his journey from Genentech to leading a pivotal trial for preventing CRS in cancer immunotherapy.
April 9, 2026
Outpost Bio CEO Jenny Yang discusses leveraging AI and metabolomics to decode the human microbiome, the next frontier in personalized medicine.
April 1, 2026
CEO Spyros Papapetropoulos shares insights on CNS drug development's future, purpose-driven leadership, and building high-performing biotech teams.
March 31, 2026
Novogaia's CEO Tess Bevers discusses using AI and mass spectrometry to unlock the vast, untapped potential of fungi for novel drug discovery.
March 30, 2026
Aphaia Pharma's co-founder discusses a novel drug that reactivates the gut's hormone system to treat obesity, aiming for global access.
March 25, 2026
EG427 CEO Philippe Chambon discusses his journey from VC to operator, pioneering pinpoint DNA medicine for neurological diseases in Europe.
March 19, 2026
Medera Biopharmaceuticals is pioneering cardiac gene therapy with a human mini-heart platform and a 100x lower-dose intracoronary delivery.
March 18, 2026
Cellares CEO Fabian Gerlinghaus on industrializing cell therapy with a fully automated platform, slashing costs & scaling to meet global demand.
March 11, 2026
Formation Bio's VP of Talent, Emily Gransky, on leveraging proprietary AI to scale an AI-native drug development company through value-based hiring.
March 10, 2026
Rejuvenate Biomed CEO Ann Belien on tackling aging with combination therapies, targeting sarcopenia, and building a biotech in Belgium.
March 9, 2026
Santhera CFO Catherine Isted on her unique career path, biotech financing, leadership lessons, and advice for women in the industry.
February 19, 2026
Arcus Biosciences CEO Terry Rosen on building a discovery-first biotech, its differentiated pipeline, and its plan to win in oncology.
February 16, 2026
Memo Therapeutics CEO Erik van den Berg on tackling BK virus in transplant patients with a potent antibody, impressive Phase 2 data, & platform tech.
February 12, 2026
Biotech leader Declan Doogan shares his journey from big pharma to startups & Causeway's groundbreaking microRNA treatment for tendon disease.
February 11, 2026
Rectify Pharma CEO Raj Devraj on the art of drug hunting, de-risking breakthrough science, strategic team building, and navigating fundraising.
February 3, 2026
Enara Bio CEO Kevin Pojasek on pioneering 'dark antigen' cancer targets, building a people-first culture, and the next frontier for solid tumors.
January 22, 2026
Delpha Therapeutics CEO Kevin Marks discusses 'activation lethality,' a novel cancer therapy, the scientist-to-CEO journey, and building a culture-first biotech.
January 15, 2026
AeroRx CEO Ahmet Tutuncu discusses a $21M Series A for a novel nebulized dual bronchodilator targeting severe COPD patients unable to use inhalers.
January 5, 2026
Resolution Therapeutics CEO Amir Hefni discusses a novel macrophage cell therapy for liver disease, now in a Phase 1/2 trial with data due in 2026.
December 19, 2025
BridgeBio executive Justin To on pioneering genetic disease treatments with a decentralized R&D model, turning academic science into patient impact.
SpliceBio CEO Miquel Vila-Perello discusses their protein splicing platform, tackling Stargardt disease, and navigating biotech fundraising.
December 16, 2025
Beacon Therapeutics CEO Lance Baldo on advancing a Phase 3 gene therapy for blindness, the advantages of ocular treatments, and global leadership.
December 15, 2025
Luba Greenwood, CEO of Gallop Oncology, discusses biotech leadership, disciplined fundraising, and the essential CEO skills for today's market.
December 9, 2025
CDR Life CEO Christian Leisner shares insights on building a biotech, pioneering T-cell engagers, and leveraging Switzerland's unique ecosystem.
